U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

Food and Drug Administration officials have opened a safety review of two injectable drugs used to protect babies and ...

The Centers for Disease Control and Prevention have issued a new recommendation to protect babies against RSV. According to the updated guidelines, infants under the age of 8 months should receive a ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

A CDC panel decided to end the universal birth dose of a hepatitis B vaccine for newborns, with some officials pointing to ...

The effectiveness of a single respiratory syncytial virus (RSV) vaccine dose declined among older adults, potentially suggesting the need for booster shots among this demographic. That is according to ...

Influenza and other respiratory viruses are starting to circulate but so far remain lower than this time last year, according to the Centers for Disease Control and Prevention. As of Oct. 7, CDC's ...